Clinical evidence suggests that benefit from the EGFR monoclonal antibody inhibitors cetuximab and panitumumab is limited to a subgroup of only 10% to 30% of CRC patients[11], [12], [13]. Here, EGFR is linked to colorectal carcinoma.